Inflammatory Biomarkers in Acute Coronary Syndromes
Authors:
- 28 February 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 113 (8) , e289-e292
Abstract
The inflammatory etiology of atherosclerosis has prompted a search for biomarkers of inflammation that predict risk for coronary artery disease and its sequelae. Within the acute coronary syndromes (ACS), inflammatory biomarkers may provide independent information regarding pathophysiology, prognosis, and optimal therapeutic strategies. Based on the hypothesis that different pathophysiological processes provide nonoverlapping information regarding risk stratification and disease management, this review series addresses biomarkers for each step in the inflammatory process leading to ACS. Parts I and II reviewed cytokines, acute-phase reactants, and biomarkers of endothelial cell activation; this part reviews biomarkers of oxidative stress and angiogenesis; part IV addresses biomarkers of extracellular matrix degradation and platelet activation. Oxidative stress leading to modification of low-density lipoprotein (LDL) is a central paradigm of atherogenesis and plaque destabilization. The antioxidant hypothesis of atherosclerosis has been bolstered by recent results suggesting that markers of oxidative stress may have prognostic significance in ACS (Table). View this table: Inflammatory Biomarkers in Acute Coronary Syndromes ### Myeloperoxidase Myeloperoxidase (MPO) is a heme protein produced by neutrophils and monocytes. MPO-dependent halides, tyrosyl radicals, and reactive nitrogen species can modify LDL and thereby promote subsequent foam cell formation.1 Patients with ACS have a reduction in intracellular neutrophil MPO across both left and right coronary beds, suggesting that widespread neutrophil activation may underlie ACS.2 In a prospective study, patients with ACS and elevated MPO levels had a statistically significant increase in the risk of death or myocardial infarction (MI) at 72 hours, 30 days, and 6 months.3 These differences in risk were attributable entirely to differences in mortality and MI during the first 72 hours. MPO levels were not related to levels of troponin T (TnT), C-reactive protein (CRP), or soluble CD40 ligand (sCD40L), suggesting that MPO provides independent prognostic information distinct from other established biomarkers. In a prospective study of …Keywords
This publication has 23 references indexed in Scilit:
- Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary SyndromesJACC, 2005
- Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL TrialCirculation, 2004
- Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?Cardiovascular Research, 2003
- Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary SyndromesCirculation, 2003
- Prognostic Significance of Angiogenic Growth Factor Serum Levels in Patients With Acute Coronary SyndromesCirculation, 2003
- Inflammation in atherosclerosisNature, 2002
- Widespread Coronary Inflammation in Unstable AnginaNew England Journal of Medicine, 2002
- Early Expression of Angiogenesis Factors in Acute Myocardial Ischemia and InfarctionNew England Journal of Medicine, 2000
- Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitroJournal of Clinical Investigation, 1999